Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory TAKC-02 study in male patients with moderate bronchial asthma
jRCTs031220218Completed
- Sponsor
- TAK-Circulator Corporation
- Start
- Mar 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of TAKC-02 in asthma (2 arms), sponsored by TAK-Circulator Corporation. Primary endpoint: Airway hyperresponsiveness test (PC20). Started Mar 2023; status: completed.
02
Drugs
TAKC-02
03
Conditions
asthma
Beyond the preview
Go deeper on jRCTs031220218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220218.